Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBITDA: 2018-2024

Historic EBITDA for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$277.5 million.

  • Phathom Pharmaceuticals' EBITDA rose 78.43% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.5 million, marking a year-over-year increase of 25.86%. This contributed to the annual value of -$277.5 million for FY2024, which is 65.84% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its EBITDA stood at -$277.5 million for FY2024, which was down 65.84% from -$167.3 million recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' EBITDA ranged from a high of -$125.7 million in FY2020 and a low of -$277.5 million during FY2024.
  • Its 3-year average for EBITDA is -$205.7 million, with a median of -$172.4 million in 2022.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' EBITDA increased by 2.97% in 2023, and later slumped by 65.84% in 2024.
  • Over the past 5 years, Phathom Pharmaceuticals' EBITDA (Yearly) stood at -$125.7 million in 2020, then dropped by 7.49% to -$135.1 million in 2021, then fell by 27.66% to -$172.4 million in 2022, then climbed by 2.97% to -$167.3 million in 2023, then slumped by 65.84% to -$277.5 million in 2024.